PMID- 33384599
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210102
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Escitalopram Ameliorates Cardiomyopathy in Type 2 Diabetic Rats via Modulation of 
      Receptor for Advanced Glycation End Products and Its Downstream Signaling 
      Cascades.
PG  - 579206
LID - 10.3389/fphar.2020.579206 [doi]
LID - 579206
AB  - Type 2 diabetes mellitus (T2DM) has been recognized as a known risk factor for 
      cardiovascular diseases. Additionally, studies have shown the prevalence of 
      depression among people with diabetes. Thus, the current study aimed to 
      investigate the possible beneficial effects of escitalopram, a selective 
      serotonin reuptake inhibitor, on metabolic changes and cardiac complications in 
      type 2 diabetic rats. Diabetes was induced by feeding the rats high fat-high 
      fructose diet (HFFD) for 8 weeks followed by a subdiabetogenic dose of 
      streptozotocin (STZ) (35 mg/kg, i. p.). Treatment with escitalopram 
      (10 mg/kg/day; p. o.) was then initiated for 4 weeks. At the end of the 
      experiment, electrocardiography was performed and blood samples were collected 
      for determination of glycemic and lipid profiles. Animals were then euthanized 
      and heart samples were collected for biochemical and histopathological 
      examinations. Escitalopram alleviated the HFFD/STZ-induced metabolic and cardiac 
      derangements as evident by improvement of oxidative stress, inflammatory, 
      fibrogenic and apoptotic markers in addition to hypertrophy and impaired 
      conduction. These results could be secondary to its beneficial effects on the 
      glycemic control and hence the reduction of receptor for advanced glycation end 
      products content as revealed in the present study. In conclusion, escitalopram 
      could be considered a favorable antidepressant medication in diabetic patients as 
      it seems to positively impact the glycemic control in diabetes in addition to 
      prevention of its associated cardiovascular complications.
CI  - Copyright (c) 2020 Ahmed, Shiha and Attia.
FAU - Ahmed, Lamiaa A
AU  - Ahmed LA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, 
      Cairo, Egypt.
FAU - Shiha, Nesma A
AU  - Shiha NA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, 
      Cairo, Egypt.
FAU - Attia, Amina S
AU  - Attia AS
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, 
      Cairo, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20201215
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7770111
OTO - NOTNLM
OT  - cardiomyopathy
OT  - depression
OT  - diabetes mellitus
OT  - escitalopram
OT  - metabolic derangements 3
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/01/02 06:00
MHDA- 2021/01/02 06:01
PMCR- 2020/12/15
CRDT- 2021/01/01 05:21
PHST- 2020/07/02 00:00 [received]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2021/01/01 05:21 [entrez]
PHST- 2021/01/02 06:00 [pubmed]
PHST- 2021/01/02 06:01 [medline]
PHST- 2020/12/15 00:00 [pmc-release]
AID - 579206 [pii]
AID - 10.3389/fphar.2020.579206 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Dec 15;11:579206. doi: 10.3389/fphar.2020.579206. 
      eCollection 2020.